Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM versus ULTRAVIST 300 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM versus ULTRAVIST 300 IN PLASTIC CONTAINER.
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM vs ULTRAVIST 300 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque contrast agent that attenuates X-rays, providing visualization of vascular and urinary structures. It is a high-osmolality ionic dimer that distributes in extracellular fluid and is excreted renally.
Iopromide is a nonionic, low-osmolality iodinated contrast medium that attenuates X-rays due to its iodine content (300 mg iodine/mL). It provides radiographic contrast in vascular and parenchymal imaging by increasing the density of blood vessels and tissues, thereby enhancing the visibility of structures and lesions.
Intra-arterial or intravenous administration; adult dose varies by procedure: for intravenous urography, 50-100 mL of 60% solution; for CT enhancement, 100-150 mL of 60% solution; maximum total dose 4.2 g iodine/kg body weight.
Intravenous administration of 1-2 mL/kg (300 mg iodine/mL) for contrast-enhanced CT; typical adult dose 100-150 mL (30-45 g iodine) given as bolus or rapid infusion.
None Documented
None Documented
1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe impairment)
Terminal half-life: 2 hours in patients with normal renal function; prolonged up to 30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Renal: 90% unchanged via glomerular filtration within 24 hours; biliary: <1%; fecal: <2%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent